Understanding how LINE1 RNA contributes to brain diseases like Alzheimer's

Regulation mechanism and functional genomics of LINE1 RNA in TDP-43 linked neurodegeneration

['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-11089409

This project explores how a specific RNA molecule, LINE1, and a protein called TDP-43, might cause brain cell damage in conditions like Alzheimer's and related dementias.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorJOHNS HOPKINS UNIVERSITY (nih funded)
Locations1 site (BALTIMORE, UNITED STATES)
Trial IDNIH-11089409 on ClinicalTrials.gov

What this research studies

This project looks into how problems with RNA, the genetic material that helps make proteins, contribute to brain diseases such as Alzheimer's and other related dementias. We know that a protein called TDP-43 often builds up abnormally in the brain cells of many patients with these conditions. This buildup might affect how another type of RNA, called LINE1 RNA, works. Our goal is to uncover the exact ways that TDP-43 dysfunction leads to issues with LINE1 RNA, which could then harm brain cells. By understanding these detailed processes, we hope to find new ways to protect brain cells from damage.

Who could benefit from this research

Good fit: This foundational research is not directly recruiting patients, but future studies stemming from this work would likely focus on individuals with Alzheimer's disease, frontotemporal dementia, or other related neurodegenerative conditions.

Not a fit: Patients without neurodegenerative conditions linked to TDP-43 pathology or LINE1 RNA dysregulation would not directly benefit from this specific research.

Why it matters

Potential benefit: If successful, this work could reveal new targets for treatments that slow or stop the progression of Alzheimer's and related dementias by addressing RNA dysfunction.

How similar studies have performed: While the role of RNA metabolism and TDP-43 in neurodegeneration is an active area of investigation, the specific focus on LINE1 RNA dysregulation caused by TDP-43 loss of function represents a novel and less explored mechanism.

Where this research is happening

BALTIMORE, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.